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Abstract
Background: Lung cancer causes approximately 1.2 million deaths per year worldwide, and non-small cell lung cancer
(NSCLC) represents 85% of all lung cancers. Understanding the molecular events in non-small cell lung cancer (NSCLC) is
essential to improve early diagnosis and treatment for this disease.
Methodology and Principal Findings: In an attempt to identify novel NSCLC related genes, we performed a genome-wide
screening of chromosomal copy number changes affecting gene expression using microarray based comparative genomic
hybridization and gene expression arrays on 32 radically resected tumor samples from stage I and II NSCLC patients. An
integrative analysis tool was applied to determine whether chromosomal copy number affects gene expression. We
identified a deletion on 14q32.2-33 as a common alteration in NSCLC (44%), which significantly influenced gene expression
for HSP90, residing on 14q32. This deletion was correlated with better overall survival (P=0.008), survival was also longer in
patients whose tumors had low expression levels of HSP90. We extended the analysis to three independent validation sets
of NSCLC patients, and confirmed low HSP90 expression to be related with longer overall survival (P=0.003, P=0.07 and
P=0.04). Furthermore, in vitro treatment with an HSP90 inhibitor had potent antiproliferative activity in NSCLC cell lines.
Conclusions: We suggest that targeting HSP90 will have clinical impact for NSCLC patients.
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Introduction
Lung cancer is the leading cause of cancer deaths worldwide
[1], and non-small cell lung cancer (NSCLC) represents 85% of
lung cancers. A better understanding of the molecular events
underlying the development and progression of the disease may
contribute to improve clinical management of NSCLC patients. A
number of genes, e.g. P53, RAS, P16 and EGFR, have been
shown to be altered in NSCLC [2]. Given the heterogeneous and
complex nature of this tumor type, it is likely that many genes
driving NSCLC tumorigenesis have yet to be identified.
Chromosomal aberrations are thought to be critical events in
human tumorigenesis, and several genomic regions frequently
harboring DNA gains (3q, 5p, 7q, 8q, 11q and 16p) and losses (3p,
4q, 5q, 6q, 8p 9p and 13q, 17q) have been identified in NSCLC
patients [3]. Using array based comparative genomic hybridiza-
tion (aCGH) and gene expression microarrays, DNA copy number
changes and gene expression can be measured throughout the
whole genome of tumor cells. By combining the data from these
analyses, it is possible to obtain an integrated genome wide view of
gene dosage aberrations and their effect on gene expression, which
might help in identifying genes important in NSCLC [4].
In the present study, we have performed an integrative analysis
of chromosomal copy number and gene expression on radically
resected tumor samples from 32 NSCLC patients. Two new
algorithms, ‘CGH call’[5] and ‘ACE-it’[6], were applied to
analyze the data. We identified a deletion on chromosome region
14q32.2-33 in 44% of NSCLC patients. This deletion was related
with improved patient survival, and was associated with decreased
expression of HSP90, a molecular chaperone for several
oncoproteins that is being explored as a novel target in anticancer
therapy. Low HSP90 expression was correlated with improved
survival in the 32 NSCLC patients analyzed initially. Further
analysis of three independent sets of NSCLC patients confirmed a
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expression. In addition, in vitro experiments show NSCLC cell
lines to be extremely sensitive to the HSP90 inhibitor 17-AAG.
Our data suggest and important role for HSP90 in NSCLC.
Methods
Patients and samples
The test set consisted of radically resected tumor specimens of
32 early stage NSCLC patients. Three patients had a survival time
of less than 30 days and were considered postoperative deaths.
Therefore these three patients are not included in the survival
analyses. Patients had a median follow up of 86 months (range 0.4-
135.5). Verbal informed consent had been obtained from all
patients and handling of samples was in accordance with protocols
approved by the ethical board ‘‘subcommissie voor de ethiek van
het mensgebonden onderzoek’’ from the VU University Medical
Center in Amsterdam.
The first validation set consisted of 140 radically resected
NSCLC patients from the European lung cancer consortium.
Patients had a median follow up of 35 months. All patients
included had had no prior malignancy, pathological tumor stage 1
or 2 (T1-2), node stage 0+1 (N0-1), no distant metastasis (M0) at
time of operation, and no residual disease after resection (R0).
None of these patients received (neo)adjuvant chemo- or
radiotherapy. The second validation consisted of 111 early stage
NSCLC patients from Bild et al. [7]. The third validation set
consisted of the publicly available ‘‘datasets 1 and 2’’ from Lu et al.
[8] and contained 54 early stage NSCLC patients. A full
description of patient characteristics of all four patient sets is
provided in Table 1.
Isolation of genomic DNA and array Comparative
Genomic Hybridization
Cryo-sections of frozen tissue samples, flanking the sections used
for RNA and DNA isolation, were verified by the study pathologist
(WM) to contain at least 50% of tumor cells. Genomic DNA was
extracted from each sample using Trizol following manufacturer
instructions (Life Technologies, Breda, The Netherlands). DNA
labeling and hybridization on CGH 30K oligonucleotide micro-
arrays was performed as described by van den IJssel et al [9].
RNA isolation and gene expression micro arrays
RNA isolation and cDNA labeling followed standard protocols.
Hybridization was performed on Agilent platform according to
standard procedures described by the manufacturer and elsewhere
[10].
Data analysis
For array CGH, spot analysis and quality control were
performed using BlueFuse version 3.2 (BlueGenome, Cambridge,
UK). Breakpoints, gains, losses and amplifications were detected
using the algorithm CGH call. This algorithm converts raw
log2ratios to absolute measures of ‘‘loss’’, ‘‘normal’’, ‘‘gain’’ or
‘‘amplification’’ by applying a segmentation algorithm combined
with a probability mixture model [11]. In order to statistically test
whether gene expression was affected by gene dosage we applied
Table 1. Clinical characteristics of test and validation patient sets
Characteristic Test set Validation set 1 Validation set 2 Validation set 3
n=32 n=140 n=111 n=54
n (%) n (%) n (%) n (%)
Gender n/a
Male 24 (75) 105 (75) 24 (44)
Female 8 (25) 35 (25) 29 (54)
Histology
Adenocarcinoma 13 (41) 43 (31) 58 (52) 14 (26)
Squamous Cell Carcinoma 15 (47) 78 (56) 53 (48) 36 (67)
Large Cell Carcinoma 3 (9) 7 (5) 0 (0) 4 (7)
Others 1 (3) 12 (8) 0 (0) 0 (0)
Smoking status n/a n/a
Never 0 (0) 7 (5)
Former 16 (50) 57 (41)
Current 11 (34) 65 (46)
Unknown 5 (16) 11 (8)
Tumor stage
IA 14 (44) 25 (18) 30 (27) 47 (87)
IB 9 (28) 68 (48) 27 (24) 7 (13)
IIA 2 (6) 5 (4) 0 (0) 0 (0)
IIB 7 (22) 42 (30) 0 (0) 0 (0)
median [range] median [range] median [range] median [range]
Age at diagnosis-years 67 22–78 64 37–79 n/a 66 48–81
Overall Survival-months 34 0.4–135.5 35 0.5–156 31 1–87.5 50 2–81
Percentages that do not reach 100% indicate missing data; n/a=information not publicly available
doi:10.1371/journal.pone.0001722.t001
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called array CGH and normalized log10 ratios for expression
arrays were used as input data. ACE-it uses the one-sided
Wilcoxon rank sum statistics to test which chromosomal copy
number aberrations recurrently affect RNA expression. Calculated
p-values are adjusted for multiple testing using the Benjamini
Hochberg method [12]. ACE-it only tests genes that meet the
criteria of contamination and balance, which are controlled
through a threshold on the number of samples. Here the threshold
was set at a fixed default setting of 9 samples, meaning that only
those chromosomal positions were taken into account that had at
least 9 samples in one CGH calling status and no more than 9 in
the other status. The entire array CGH data set of the test series
(n=32) is available at the GEO database (http://www.ncbi.nlm.
nih.gov/projects/geo, accession number GSE7878). The gene
expression data of both the test set (n=32) and validation set 1
(n=140) for the 359 genes identified by ACE-it is available at
the Array Express database (www.ebi.ac.uk/aerep/login, acces-
sion number Array design: A-MEXP-749, Experiment data:
E-TABM-270).
Gene expression data of validation set 2 was obtained using
Affymetrix Hu133plus2 chips (GEO accession number GSE3141).
The mean value of the MAS5 calculated signal intensities of four
probesets detecting HSP90AA1 was used in our calculations.
The third validation set contained gene expression data from
Affymetrix Hu95 and Hu133 chips (GEO accession number
GSE6253). The Hu95 chip contained one probeset detecting
HSP90AA1 and the Hu133 chip contained four probesets, of
which the mean value of the RMA calculated signal intensities was
used in our calculations.
Statistics
An univariate cox regression analysis was performed to
investigate relation of gene expression values with survival time.
Survival curves were constructed using the Kaplan Meier method
and differences in overall were evaluated using the log-rank test. In
the test set, three patients with less than 30 days survival time were
excluded from the survival analysis, as their death was considered
surgical mortality. To determine the independent effects of HSP90
expression, histologic subtype, tumor stage, age and gender, a
multivariate cox regression analysis was performed. A P value of
less than 0.05 was considered statistically significant.
Multiplex Ligation dependent Probe Amplification
(MLPA)
For Multiplex Ligation dependent Probe Amplification
(MLPA), the subtelomere probe set P070 (MRC Holland,
Amsterdam, The Netherlands) containing a probe located within
the band 14q32.33 (region 104874216 to 105070384) was used.
MLPA was performed according to manufacturer’s instructions
using 100ng DNA as input. DNA isolated from blood of a pool of
healthy donors was used as reference sample. Probe signals were
normalized by dividing the peak area of chromosome 14q by the
peak area of chromosome 14p. MLPA generated 14q/14p ratios
are plotted against the mean normalized log2ratios of the oligos in
area 104787271-105071522 from the array (total of 11 oligos).
This region covers the region of the MLPA probe.
Quantitative RT-PCR
In order to validate expression values obtained via gene
expression arrays, we performed quantitative real-time PCR using
TaqmanH technology and the ABI PRISM 7500 Sequence
Detection System instrument equipped with the SDS version
1.3.0 software (Applied Biosystems, Foster City, CA, USA).
Forward and reverse primers and probes were designed
and produced by Applied Biosystems for HSP90AA1
(Hs00743767_sH), and for the endogenous control gene GUSB
Table 2. Chromosomal regions with gains and losses present
in .20% of NSCLC patients analyzed
Gains
Chromosome Position Band
Start End Start End
3 95285925 126749042 3q11.2 3q21.2
3 130358402 199253846 3q21.3 3q29
5 237445 50384805 5p15.33 5q11.1
7 8160729 26912147 7p21.3 7p15.2
7 102223012 123576527 7q22.1 7q31.32
7 129933159 137018487 7q32.2 7q33
8 56600324 134124595 8q12.1 8q24.22
18 201402 8190420 18p11.32 18p11.23
Losses
Chromosome Position Band
Start End Start End
1 794287 6218763 1p36.33 1p36.31
2 218493156 220321649 2q35 2q35
2 239090261 242663692 2q37.3 2q37.3
3 46687093 52531946 3p21.31 3p21.1
4 76846 9755709 4p16.3 4p16.1
5 175887337 176879711 5q35.2 5q35.3
7 249767 2725138 7p22.3 7p22.3
7 44521369 44915245 7p13 7p13
8 142432747 146195957 8q24.3 8q24.3
9 127235226 138292321 9q33.3 9q34.3
10 132822632 135257796 10q26.3 10q26.3
11 189965 3616421 11p15.5 11p15.4
11 63500334 67523686 11q13.1 11q13.2
12 131354356 131915096 12q24.33 12q24.33
14 99160871 106031435 14q32.2 14q32.33
16 37498 4794625 16p13.3 16p13.3
16 27698990 31630451 16p11.2 16p11.2
16 66028796 66259430 16q22.1 16q22.1
16 82507053 88765762 16q24.1 16q24.3
17 33712 1922929 17p13.3 17p13.3
17 73628337 78645922 17q25.3 17q25.3
19 239096 19651642 19p13.3 19p13.11
19 54738209 56174941 19q13.33 19q13.41
19 60553920 60910750 19q13.42 19q13.42
19 63553599 63784634 19q13.43 19q13.43
20 3156113 3846872 20p13 20p13
20 59726290 62367223 20q13.33 20q13.33
21 42368792 46898780 21q22.3 21q22.3
22 36290852 36537184 22q13.1 22q13.1
doi:10.1371/journal.pone.0001722.t002
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volume that contained 50 ng of cDNA, 16 TaqMan Universal
PCR Master Mix, and the primer and probe sets for HSP90AA1
and GUSB. Each sample was analyzed in duplicate, and the
average threshold cycle (Ct) values of each sample for GUSB, were
subtracted from the average Ct values for HSP90AA1. Taqman-
generated DCt values were log transformed to expression values
and plotted against the Dlog2ratios between GUSB and
HSP90AA1 from the expression array.
Cell growth inhibition studies
Growth inhibition following in vitro exposure to the clinically
used Hsp90 inhibitor 17-AAG (InvivoGen, San Diego, CA) was
examined in 4 EGFR wild type NSCLC cell lines (H460, H157,
H441 and A549, obtained from Drs. P. Dennis and F. Kaye, NCI,
Bethesda, MD). Briefly, 10
5 cells were seeded in 6-well tissue
culture plates (Sigma-Aldrich, St. Louis, MO), allowed to adhere,
and then continuously exposed to various concentrations of 17-
AAG (0, 10, 30, 100, 300, 1000 nM) for 24, 48, or 72 hours. At
each time point, cells were detached from the wells, incubated with
trypan blue, and viable (trypan blue-excluding) cell number was
determined in triplicate using a hemacytometer. The mean cell
number with standard error bars is shown at each time point. In
addition, the IC50 (drug concentration at which 50% growth
inhibition is obtained) of 17-AAG at 72 hours was determined for
each cell line.
Results
Gene dosage-related gene expression changes in NSCLC
Chromosomal aberrations were abundant in the 32 NSCLC
patients analyzed. In order to identify breakpoints of gains and
losses we applied the algorithm CGH call [11]. In Table 2 the
chromosomal regions in which gains or losses were present in at
least 20% of patients are listed. The statistical tool ACE-it [6] was
used to determine whether gene copy number affected gene
expression. A total of 359 transcripts turned out to be significantly
affected by copy number. In Figure 1 the areas of affected genes
are indicated for 32 NSCLC patients, shown in green (gained
regions) or red (lost regions).
An univariate cox regression survival analysis was performed for
expression of all 359 genes that were identified to be influenced by
copy number (see supplementary table S1). After multiple testing
correction (using the Benjamini Hochberg method) none of 359
genes remained significant for survival on this small patient set
(n=32). The top list of genes correlated with survival (ranked on
raw p-values) contained mainly genes located on chromosomes 3
and 5 gained regions. We also observed one gene in the top-20 list,
HSP90AA1, located on chromosome 14. The HSP90AA1 gene
(generally referred to as HSP90), located on 14q32.2, was the only
gene in this region with significantly reduced expression in patients
affected by loss of this region (P=0.05). These observations
prompted us to investigate this locus in more detail.
Figure 1. Percentage of called gains and losses and their effect on gene expression in 32 NSCLC patients. Summary plot for called gains
and losses in 32 resected NSCLC patients with DNA copy number changes indicated in grey. Positive values indicate the percentage of samples found
with a gain. Negative values indicate the percentage of samples harboring a loss at the specified chromosome location. Genes in specified regions
affected by copy number gain are indicated in green and genes affected by copy number loss are indicated in red. A selection of affected genes is
indicated. The full list of 359 affected transcripts can be found in supplementary table S1.
doi:10.1371/journal.pone.0001722.g001
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expression correlation with survival
We investigated the correlation of the recurrent tight deletion at
region 14q32.2-33, with survival. Interestingly, patients in whom
this region was deleted had an improved overall survival (OS)
compared to patients harboring a normal gene dosage at this locus
(5 year OS 69% vs. 41%, P=0.004-Figure 2A).
In order to investigate HSP90 expression in relation with
survival, we divided the 32 patients into two groups based on their
survival status two years after tumor resection. About half of the
patients were categorized as ‘‘high-risk’’ and half as ‘‘low-risk’’. To
identify whether both risk groups could be discriminated using
gene expression of HSP90, we constructed Kaplan Meier survival
estimates for two equally large groups with ‘‘low’’ and ‘‘normal’’,
based on the median HSP90 expression. Low expression of
HSP90 was associated with better overall survival (5 year OS 70%
vs. 40%, P=0.13–Figure 2B) although differences between the
two groups were initially not significant due probably to a
combination of a low magnitude of the difference and a low
number of patients analyzed.
Technical validation of 14q deletion and HSP90
expression
To validate the deletion observed in region 14q32.2-33 we
performed multiplex ligation dependent probe amplification [13]
(MLPA) analysis using a subtelomere probeset containing a probe
in region 14q32.33. The correlation coefficient (R
2) between the
loss of this area detected by array CGH and by MLPA was 0.439.
To validate the HSP90 expression data obtained with micro-
arrays we performed quantitative RT PCR using the TaqmanH
technology. A good correlation between the expression of HSP90
measured with the two different techniques was observed
(R
2=0.6431).
Validation of HSP90 expression and relation with survival
in independent patient series
To further investigate the association between low HSP90
expression and NSCLC patient prognosis, we used three
independent validation sets of NSCLC patients. In all three
patient sets, the ‘‘low-risk’’/‘‘high-risk’’ patient distribution across
patient cohorts was approximately two-thirds vs. one-third.
Therefore, we used the 33-percentile of HSP90 expression as cut
off for separation of patients with ‘‘normal’’ (i.e. high-risk) and
‘‘low’’ (i.e. low-risk) expression. For all three validation sets, low
expression of HSP90 was correlated with improved overall
survival. This correlation was significant for the first and third
validation sets (P=0.003 and P=0.04), and borderline significant
for the second set (P=0.07) (Figure 3). Multivariate analysis
revealed that HSP90 prognostic value was independent from the
stage, histologic subtype, age and gender of patients (Table 3).
Validation of Hsp90 as a viable molecular target in a
panel of NSCLC cell lines
Hsp90 is a molecular chaperone that stabilizes several
oncoproteins, including EGFR, and constitutes a novel potential
target for anticancer therapy. The data above showed that Hsp90
expression level is a prognostic indicator of long-term survival in a
large series of NSCLC patients, and suggest that Hsp90 inhibitors
may have broader utility in this disease than previously
recognized. To examine this possibility, we tested whether
pharmacologic inhibition of Hsp90 function would impact the in
vitro cell growth of a panel of NSCLC cell lines. The growth of
Figure 2. Loss of 14q32.2-32.33 chromosomal region and HSP90 expression in relation with survival. (A) Kaplan-Meier curves for overall
survival are shown for 29 patients in relation to gene dosage in chromosome region 14q32.33. (B) Overall survival for 29 patients in relation to HSP90
expression. Low expression was defined as expression lower than the median of the total 32 samples, ‘‘normal’’ expression was defined as higher
than the median of 32 samples. Three of 32 patients included in the analysis of gene dosage and expression were excluded from the survival analysis
because of a survival time of less than 30 days.
doi:10.1371/journal.pone.0001722.g002
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inhibited, in a dose- and time-dependent manner, by sub-
micromolar concentrations of 17-AAG, an Hsp90 inhibitor [14]
currently in phase II clinical trial (Figure 4). At 72 hours, the IC50
was below 50 nM 17-AAG in all cases, and higher drug
concentrations consistently resulted in marked cytotoxicity.
Discussion
Based on array-CGH data in NSCLC, it has been shown that
multiple molecular carcinogenesis pathways exist that are most
likely related to gender and smoking habits [15]. Furthermore, it
was shown that there is a large overlap between aberrations
observed in the adenocarcinoma and squamous cell carcinoma
subtype, except for 3q gains which seem to be more specific for the
squamous cell carcinoma subtype [16]. Various gene expression
signatures have been correlated to survival of NSCLC patients
[17–19]. In addition, molecular studies have allowed the
development of personalized treatment approaches in several
tumor types [20–22]. However, it is likely that many cancer-
related target genes have not been identified yet. In this regard,
integrated genome wide screening of copy number changes and
gene expression using microarrays has been recently carried out in
various tumor types to identify genes whose expression is affected
by gene dosage [4,23–26]. These studies aim to identify novel
cancer-related genes and to define novel biomarkers for response
or prognostic signatures. In both NSCLC and ductal pancreatic
cancer, two focal amplifications of 8p12 and 20q11 have been
studied in detail leading to two candidate genes (WHSC1L1 and
TPX2) important in these diseases [16]
We here performed an integrated genome wide screening of
gene copy number changes and gene expression in 32 radically
resected NSCLC patients, in order to identify novel NSCLC-
related genes. By using ACE-it, a novel informatics tool for
integration of gene dosage and gene expression data, we identified
359 transcripts to be significantly affected by copy number. A cox
survival analysis on all 359 genes revealed no significant relation
after multiple testing. The top list of genes related to survival
mainly included genes residing on gained regions 3q and 5p.
These regions cover many genes and to pinpoint the gene of most
importance is a challenging task. Further investigations should
elucidate the importance of these genes in relation to NSCLC, in
particular of those in the top list of correlation with survival such as
SLC45A2, WDR70 and NIPBL (see supplementary table S1). In
this paper we focused on the recurrent deletion on chromosome 14
and the gene HSP90, which was also in the top list of relation with
survival and not previously investigated in detail. Deletion of
region 14q32.2-33 was correlated with improved survival, further
suggesting that it may contain one or more genes related to
NSCLC progression. Deletion of this region has been previously
described by one group reporting genomic aberrations in NSCLC,
but was not investigated in further detail [27]. Out of the 109
genes mapping to the 14q32.2-33 region, HSP90 was the only
gene with significantly lower expression in patients harboring the
14q32.2-33 deletion. In the initial series of 29 patients (3 patients
excluded from survival analysis), we observed improved survival in
patients with lower levels of HSP90. The association between
HSP90 expression levels and NSCLC patient prognosis was
confirmed to be significant in three independent validation sets of
NSCLC patients. Multivariate analysis including stage, histology,
age and gender showed that HSP90 remained independently
related to survival.
A critical issue in defining ‘‘low’’ and ‘‘normal’’ expression is the
choice of an appropriate cut off value. In the initial analyses we
used the median of expression ratios as cut off between ‘‘low’’
and ‘‘normal’’ expression, since the low-risk and high-risk
separation of patients was equal. However, in the validation
Table 3. Multivariate cox analysis of HSP90 expression and
survival
Validation set 1 Validation set 2 Validation set 3
HR 95% CI
P
value HR 95% CI
P
value HR 95% CI
P
value
HSP90 0.41 0.22–0.750.004 0.52 0.27–0.960.036 0.24 0.05–1.070.061
STAGE 1.47 1.11–1.950.008 n/a 0.51 0.13–1.940.320
HISTOLOGY 0.84 0.59–1.190.320 0.71 0.41–1.210.210 0.48 0.18–1.290.140
AGE 0.99 0.95–1.030.550 n/a 1.00 0.94–1.070.900
GENDER 0.26 0.09–0.720.010 n/a 1.23 0.45–3.340.690
HR=Hazard Ratio; n/a=data not publicly available or incomplete
doi:10.1371/journal.pone.0001722.t003
Figure 3. HSP90 expression and survival in three validation sets of NSCLC patients. Overall survival for (A) 140 patients with NSCLC,
validation set 1 (B) 111 NSCLC patients, validation set 2 and (C) 54 patients with NSCLC, validation set 3. The cut off for distinction between low and
‘‘normal’’ expression was based on the 33-percentile of expression values.
doi:10.1371/journal.pone.0001722.g003
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balanced (two thirds versus one third). Consequently the cut off
values used in these data sets was not the median value, but the 33-
percentile.
In this study, using a genome wide integrative analysis of gene
copy number and expression we were able to identify expression of
HSP90 as an important gene in early stage NSCLC patients.
HSP90 is a chaperone protein involved in the stabilization of
multiple oncoproteins such as EGFR, Her-2 and Akt [28]. Recent
work has shown that HSP90 plays a role in maintaining the active
conformation of EGFR and in particular EGFR mutants [29,30].
We show here that several NSCLC cell lines bearing wild-type
EGFR are sensitive to HSP90 inhibition, indicating that the
inhibitory effect of 17-AAG can not be solely attributed to mutant
EGFR. HSP90 has been recently recognized as a potential cancer
therapeutic target and investigations of HSP90 inhibitors are
ongoing [31,32]. In this regard, glioblastoma cells overexpressing
EGFR, but resistant to inhibition by EGFR kinase inhibitors, were
sensitive to HSP90 inhibition [33]. Therefore, while Hsp90 may
be required to stabilize over-expressed or mutated EGFR, our
data support a more wide-ranging and complex role for Hsp90 in
mediating NSCLC growth and survival. The low nanomolar
sensitivity observed in the 4 cell lines tested in our experiments, is
in agreement with other published reports of highly 17-AAG
sensitive tumor cell lines [34–36]. These concentrations are readily
achievable in patients for prolonged time periods using current
scheduling and dosing regimens [37].
In summary, the observation that HSP90 expression level is a
prognostic factor for NSCLC patient survival (independent of
EGFR mutational status), coupled with the extreme sensitivity of
EGFR wild type NSCLC cells to the Hsp90 inhibitor 17-AAG,
suggests that Hsp90 inhibitors may have greater clinical utility in
NSCLC than has been previously considered and warrants further
investigation of the dependence of other proto-oncogenes on this
chaperone protein in NSCLC.
Supporting Information
Table S1
Found at: doi:10.1371/journal.pone.0001722.s001 (0.03 MB
PDF)
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